Interactive Video Gaming Device Could Aid MS Patients
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Using Kinect motion-capture camera may improve evaluation of gait pathology in multiple sclerosis patients by increasing objectivity in diagnosis and treatment monitoring (Photo courtesy of the Montreal Neurological Institute & Hospital and McGill University).
A commonly used 3D depth-sensing camera could become a low-cost means of monitoring treatment effectiveness for walking difficulties of patients with gait-impairing diseases such as multiple sclerosis (MS).
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read moreMolecular Diagnostics
view channel
ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
Selecting surgery versus non-surgical management in early-stage breast cancer can be challenging for older patients, who often balance disease control with comorbidities and quality-of-life considerations.... Read more
WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
Early detection of cancer remains difficult across many tumor types, and current single‑cancer screening modalities leave significant gaps. Blood‑based, multi‑cancer assays aim to detect tumor signals... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







